Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TransMedics (TMDX) Short-term Investments (2019 - 2022)

TransMedics has reported Short-term Investments over the past 4 years, most recently at $27.7 million for Q2 2022.

  • Quarterly results put Short-term Investments at $27.7 million for Q2 2022, down 68.14% from a year ago — trailing twelve months through Jun 2022 was $27.7 million (down 68.14% YoY), and the annual figure for FY2021 was $66.9 million, down 33.83%.
  • Short-term Investments for Q2 2022 was $27.7 million at TransMedics, down from $54.1 million in the prior quarter.
  • Over the last five years, Short-term Investments for TMDX hit a ceiling of $111.3 million in Q3 2020 and a floor of $27.7 million in Q2 2022.
  • Median Short-term Investments over the past 4 years was $67.4 million (2019), compared with a mean of $70.4 million.
  • Biggest five-year swings in Short-term Investments: skyrocketed 91.12% in 2021 and later tumbled 68.14% in 2022.
  • TransMedics' Short-term Investments stood at $60.6 million in 2019, then skyrocketed by 66.78% to $101.1 million in 2020, then tumbled by 33.83% to $66.9 million in 2021, then plummeted by 58.58% to $27.7 million in 2022.
  • The last three reported values for Short-term Investments were $27.7 million (Q2 2022), $54.1 million (Q1 2022), and $66.9 million (Q4 2021) per Business Quant data.